Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Non Small Cell Lung Cancer

Jurisdiction:

South Korea

Organ System:

Lung

Funding Organizations:

  • Korean Ministry of Science and ICT (MSIT), S. Korea
  • Korea University, S. Korea

Research Organizations:

  • Kyung Hee University, S. Korea
  • Korea University, S. Korea
  • DGIST, S. Korea
  • Hanyang University, S. Korea
  • Asan Medical Center, S. Korea

Principal Investigators:

  • Kwang Pyo Kim
  • Joon-Yong An
  • Se Jin Jang
  • Seungjin Na
  • Eunok Paek
  • Min-Sik Kim

Publication:

External Links:

Non-small cell lung cancer (NSCLC) is histologically classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC). However, some tumors are histologically ambiguous and other pathophysiological features or microenvironmental factors may be more prominent. Here we report integrative multiomics analyses using data for 229 patients from a Korean NSCLC cohort and 462 patients from previous multiomics studies. Histological examination reveals five molecular subtypes, one of which is a NSCLC subtype with PI3K-Akt pathway upregulation, showing a high proportion of metastasis and poor survival outcomes regardless of any specific NSCLC histology. Proliferative subtypes are present in LUAD and LSCC, which show strong associations with whole genome doubling (WGD) events. Comprehensive characterization of the immune microenvironment reveals various immune cell compositions and neoantigen loads across molecular subtypes, which predicting different prognoses. Immunological subtypes exhibit a hot tumor-enriched state and a higher efficacy of adjuvant therapy.

x